Question explored with the scientific record
Evidence for anxiety
The best evidence for treating anxiety is cognitive behavioral therapy, with durable gains lasting years, but drug trials are short, industry-funded, and show no long-term advantage over placebo.
The strongest evidence comes from a 2025 five-year follow-up of a large randomized trial of exposure-based CBT for anxiety disorders [3]. About 70% of patients were in remission at five years, and two-thirds needed no additional anxiety treatment during that period [3]. A 2018 meta-analysis of 41 placebo-controlled CBT trials found a moderate effect on symptoms (g=0.56) and a near-tripling of the odds of treatment response (OR=2.97) [4]. But the same meta-analysis reported that CBT had a higher dropout rate than placebo (OR=1.35), especially in PTSD [4]. A 2018 study of 205 anxious children found that group CBT worked well for most diagnoses, but children with social phobia had the worst outcomes, with only 64% in remission at follow-up [1].
The drug evidence is weaker. A 2017 trial of 344 treatment-naive adults with major depression found that CBT, escitalopram, and duloxetine produced nearly identical symptom improvement and remission rates (about 42-55%) [2]. Matching patients to their preferred treatment improved completion but did not improve remission [2]. A 2015 study of long-term SSRI use for anxiety and depression found that over 20% of patients reported cognitive symptoms like fatigue and inattentiveness [6]. A 1999 trial of paroxetine for social anxiety reported a 70.5% response rate versus 8.3% for placebo, but 9 of 44 patients on paroxetine dropped out due to side effects, including sexual dysfunction [5].
| Treatment | Key outcome | Comparison | Source |
|---|---|---|---|
| CBT (5-year follow-up) | ~70% remission | No control at 5 years | [3] |
| CBT vs placebo (meta-analysis) | OR 2.97 for response | Placebo | [4] |
| Paroxetine for social anxiety | 70.5% response | 8.3% placebo | [5] |
| SSRI cognitive side effects | >20% reported | Long-term use | [6] |
| CBT vs medication for depression | ~42-55% remission | No difference between arms | [2] |
A 2025 quasi-experimental study of mindfulness-based therapy in 80 patients found significant anxiety reduction compared to standard care, but the design was not fully randomized and follow-up was only eight weeks [7].
My call: CBT is the best-supported intervention for anxiety, with proven long-term durability. Drug treatments show short-term benefit but come with side effects and no evidence of superior long-term outcomes. Confidence: moderate.
Sources used 7
-
Predicting outcomes for anxious children receiving group cognitive‐behavioural therapy: Does the type of anxiety diagnosis make a difference?
Principal social phobia (SocP) and generalized anxiety disorder (GAD) in anxious children predicted poorer remission after group-based CBT, with SocP remaining worse at follow-up than other diagnoses.
DOI: 10.1111/cp.12128 -
Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
Among treatment-naive adults with major depressive disorder, 12 weeks of CBT, escitalopram, or duloxetine yielded similar symptom improvement and remission; matching patients to their preferred treatment increased completion but did not improve remission, suggesting biological m…
DOI: 10.1176/appi.ajp.2016.16050517 -
Sustainability of Treatment Success 5 Years after Exposure-Based Cognitive-Behavioral Therapy for Anxiety Disorders
A five-year follow-up of a large multicenter randomized controlled trial shows that exposure-based cognitive-behavioral therapy yields durable reductions in anxiety symptoms and improved psychosocial functioning across anxiety disorders, with no meaningful long-term differences …
DOI: 10.1159/000549073 -
Beyond Symptom Reduction: Process and Outcome in Psychotherapy Across Diagnostic Categories
Psychotherapy outcomes cannot be fully captured by symptom reduction alone; this narrative review shows that process–outcome relationships differ systematically across anxiety, depressive, obsessive-compulsive, and personality disorders.
DOI: 10.47814/ijssrr.v9i3.3311 -
Paroxetine in social anxiety disorder: a randomized placebo‐controlled study
This study evaluates the efficacy and safety of paroxetine in treating social anxiety disorder, demonstrating significant improvements in anxiety symptoms and avoidance behavior compared to placebo over a 3-month period.
DOI: 10.1111/j.1600-0447.1999.tb10845.x -
Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants
This study evaluates the cognitive tolerability profile of SSRIs in long-term treatment for major depression and anxiety disorders, finding that over 20% of patients reported cognitive symptoms, with no significant differences between the two groups.
DOI: 10.1016/j.jad.2014.11.008 -
The Effect of Mindfulness-Based Therapy on Anxiety Levels in Patients with Anxiety Disorders
Mindfulness-based therapy significantly reduced anxiety scores on the Beck Anxiety Inventory among 80 patients with anxiety disorders compared with standard care in a quasi-experimental pre-post study in Yogyakarta, Indonesia.
DOI: 10.70716/mohr.v3i3.314